Renal Replacement Therapy in the Critical Care Setting

Area of Science:

• Nephrology
• Critical Care Medicine
• Intensive Care Unit (ICU) Management

Background:

• Acute kidney injury (AKI) frequently necessitates renal replacement therapy (RRT) in critically ill patients.
• Current RRT practices in intensive care units (ICUs) are supported by limited evidence.
• Recent randomized control trials (RCTs) have introduced new questions regarding RRT's role in critical care.

Purpose of the Study:

• To review the current evidence and understanding of renal replacement therapy (RRT) in the management of critically ill patients with acute kidney injury (AKI).
• To discuss the optimal timing, dosing, and modality of RRT in the ICU setting.
• To evaluate anticoagulation strategies and emerging therapies in RRT.

Main Methods:

• Review of recently published randomized control trials (RCTs) and existing literature on RRT in critical care.
• Analysis of evidence regarding timing, dosing, and different modes of RRT.
• Evaluation of anticoagulation methods, specifically regional citrate anticoagulation versus heparin in continuous renal replacement therapy (CRRT).

Main Results:

• Optimal timing and dosing of RRT remain debatable, with current evidence favoring a delayed strategy and less intensive dosing.
• Various RRT modes show no definitive benefits in mortality or renal function preservation.
• Regional citrate anticoagulation is preferred for CRRT due to a lower bleeding risk compared to heparin.
• RRT can support cardiac failure, but hemoperfusion is not recommended for sepsis.

Conclusions:

• The evidence base for RRT in AKI within ICUs is limited, necessitating further high-quality research.
• A delayed initiation and less intensive dosing strategy for RRT may be considered in critically ill patients.
• Regional citrate anticoagulation is the recommended anticoagulation method for CRRT to minimize bleeding risks.
• Emerging therapies like hemoperfusion are not currently indicated for sepsis management.